Join us online for SLGT2 Inhibitions Update 2021: 9th and 10th, July 2021 at 15:30-18:00H CEST. Discover how the leading heart failure and cardiorenal medical experts are applying the latest insights from clinical trials into clinical practice.
Overview
Latest clinical data & clinical practice guidelines
Organized with scientific co-chairs Stefan Anker and Andrew Coats, the event includes presentations and live panel discussions with a host of international thought-leaders.The SGLT2 updates 2021 conference will cover the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
Meet The Expert - Translating insights into clinical practice
Each day will include breakouts sessions to discuss the implications in treatment of specific patient subgroups including patients with comorbidities. Attendees will have the opportunity to ask questions during these live discussions.
Latest clinical data & clinical practice guidelines
Organized with scientific co-chairs Stefan Anker and Andrew Coats, the event includes presentations and live panel discussions with a host of international thought-leaders.The SGLT2 updates 2021 conference will cover the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
Meet The Expert - Translating insights into clinical practice
Each day will include breakouts sessions to discuss the implications in treatment of specific patient subgroups including patients with comorbidities. Attendees will have the opportunity to ask questions during these live discussions.
Countdown to conference
SGLT2 inhibition in cardiorenal disease
Educational Objectives
  • list icon
    Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
  • list icon
    Evaluate the safety and cardiorenal benefits of glucose-lowering agents
  • list icon
    Apply findings from clinical trials into clinical practice
  • list icon
    Implement the new guidelines of the HFA of the ESC in clinical practice
  • list icon
    Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
Chairs
Stefan-Anker
Stefan Anker
Germany
Andrew-Coats
Andrew Coats
UK/Australia
Day 1: July 9, 2021 | 15:30-18:00 CEST (Paris)
Presentations and Discussion
  • SGLT2 inhibitors for diabetic patients with increased CV risk: how the success story started
    Bernard Zinman, Toronto, ON, Canada
  • SGLT2 inhibitors: evolution from glucose lowering to cardiorenal protection
    Milton Packer, Dallas, TX, USA
  • SGLT2 inhibitors in cardiology indications: the data
    John J. V. McMurray, Glasgow, UK
  • SGLT2 inhibitors in chronic kidney disease: the data
    Katherine R. Tuttle, Spokane, WA, USA
  • Panel Discussion
Meet The Expert Breakout Sessions
  • Totality of evidence for the cardiorenal patient
    Alice Cheng, Toronto, ON, Canada
    Milton Packer, Dallas, TX, USA
  • SGLT2i and QoL improvement
    Shelley Zieroth, Winnipeg, MB, Canada
    John A. Spertus, Kansas City, MI, USA
  • Age groups and vulnerable patients
    Gerasimos Filippatos, Athens, Greece
    Giuseppe Rosano, London, UK
Day 2: July 10, 2021 | 15:30-18:00 CEST (Paris)
Presentations and Discussion
  • How do SGLT2 inhibitors bring about cardiorenal benefits?
    Subodh Verma, Toronto, ON, Canada
  • Totality of evidence in heart failure
    Deepak L. Bhatt, Boston, MA, USA
  • Trial results coming out soon
    Stefan D. Anker, Berlin, Germany
  • Heart failure guidelines – July 2021 update
    Marco Metra, Brescia, Italy
  • Panel Discussion
Meet The Expert Breakout Sessions
  • Early treatment initiation in the hospital setting
    Mark C. Petrie, Glasgow, UK
    Deepak L. Bhatt, Boston, MA, USA
  • Managing patients with comorbidities (T2D & CKD)
    Paola Fioretto, Padova, Italy
    Katherine R. Tuttle, Spokane, WA, USA
  • Interdisciplinary collaboration and care transitions
    Subodh Verma, Toronto, ON, Canada
    Faiez Zannad, Nancy, France
Industry-Sponsored Satellite Symposia
  • Details coming soon
Presentations and Discussion
  • How do SGLT2 inhibitors bring about cardiorenal benefits?
    Subodh Verma, Toronto, ON, Canada
  • Totality of evidence in heart failure
    Deepak L. Bhatt, Boston, MA, USA
  • Trial results coming out soon
    Stefan D. Anker, Berlin, Germany
  • Heart failure guidelines – July 2021 update
    Marco Metra, Brescia, Italy
  • Panel Discussion
Meet The Expert Breakout Sessions
  • Early treatment initiation in the hospital setting
    Mark C. Petrie, Glasgow, UK
    Deepak L. Bhatt, Boston, MA, USA
  • Managing patients with comorbidities (T2D & CKD)
    Paola Fioretto, Padova, Italy
    Katherine R. Tuttle, Spokane, WA, USA
  • Interdisciplinary collaboration and care transitions
    Subodh Verma, Toronto, ON, Canada
    Faiez Zannad, Nancy, France
Sponsors